injectable vs oral semaglutide Shines as Weight Loss Therapy Injectable vs Oral Semaglutide: The

Description

Further, these changes in appetite and eating behaviors were reported more frequently in the retatrutide 4/8/12 mg group compared to the retatrutide 1 mg group

The most frequent gastrointestinal side effects include: Nausea and vomiting : Very common, typically most pronounced during dose escalation Diarrhoea : Common to very common, though usually mild to moderate Constipation : Can occur due to delayed gastric emptying and reduced gut motility Abdominal pain and discomfort : Common Dyspepsia and gastro-oesophageal reflux : May worsen in susceptible individuals Other important adverse effects include: Gallbladder disorders : Cholelithiasis and cholecystitis have been reported, particularly with weight loss Dehydration and acute kidney injury : May occur secondary to severe gastrointestinal symptoms Hypoglycaemia : Risk increases when used with insulin or sulfonylureas, which may require dose adjustment Current limited evidence does not suggest an increased risk of inflammatory bowel disease (IBD) flares with GLP-1 agonists, though more data are needed

Patients who have a family history of medullary thyroid carcinoma, a very rare form of thyroid cancer, should also not take GLP-1 medications

A 2024 commentary in Lancet Diabetes & Endocrinology reported that GLP-1 users can lose anywhere from 25 to 39% of their muscle mass over a 9-to-18-month period, which is a rate of decline several times greater than normal age-related muscle loss

Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial